Hematopoietic growth factors in drug-induced agranulocytosis

Area of Science:

• Hematology
• Pharmacology

Background:

• Drug-induced agranulocytosis (DIA) is a life-threatening condition characterized by a severe reduction in neutrophils.
• Hematopoietic growth factors are recognized for their therapeutic potential in managing DIA.
• Systemic infection is a common complication in patients with DIA.

Purpose of the Study:

• To evaluate the efficacy and safety of granulocyte macrophage - colony stimulating factor (GM-CSF) in treating drug-induced agranulocytosis.
• To assess the impact of GM-CSF on neutrophil recovery and clinical outcomes in patients with DIA.

Main Methods:

• A case series of nine patients diagnosed with DIA and treated with GM-CSF at a dose of 300 microg/day.
• Monitoring of absolute neutrophil count (ANC) to determine the time to recovery.
• Assessment of clinical outcomes, including systemic infection, morbidity, and mortality.

Main Results:

• All nine patients received GM-CSF treatment for DIA.
• The mean time to achieve an absolute neutrophil count of 0.5 x 10(9)/L was three days.
• One patient died due to multiorgan failure; however, no adverse events were associated with GM-CSF administration.

Conclusions:

• GM-CSF is a valuable therapeutic agent for drug-induced agranulocytosis.
• GM-CSF effectively shortens the duration of neutropenia.
• The use of GM-CSF can reduce morbidity and mortality in patients with DIA.